A BILL 
To amend title 35, United States Code, to clarify and im-
prove the process for subsection (k) applicants to resolve 
patent infringement claims for biological products (com-
monly known as the ‘‘patent dance’’), and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Prescrip-
4
tions for Patients Through Improvements to Patent Liti-
5
gation Act of 2019’’. 
6
00:09 Aug 13, 2019
H3991
2 
•HR 3991 IH
SEC. 2. TITLE 35 AMENDMENTS. 
1
(a) IN GENERAL.—Section 271(e) of title 35, United 
2
States Code, is amended— 
3
(1) in paragraph (2)(C), in the flush text fol-
4
lowing clause (ii), by adding at the end the fol-
5
lowing: ‘‘With respect to a submission described in 
6
clause (ii), the act of infringement shall extend to 
7
any patent that claims the biological product, a 
8
method of using the biological product, or a method 
9
or product used to manufacture the biological prod-
10
uct.’’; and 
11
(2) by adding at the end the following: 
12
‘‘(7)(A) Subject to subparagraphs (C), (D), and (E), 
13
if the sponsor of an approved application for a reference 
14
product, as defined in section 351(i) of the Public Health 
15
Service Act (42 U.S.C. 262(i)) (referred to in this para-
16
graph as the ‘reference product sponsor’), brings an action 
17
for infringement under this section against an applicant 
18
for approval of a biological product under section 351(k) 
19
of such Act that references that reference product (re-
20
ferred to in this paragraph as the ‘subsection (k) appli-
21
cant’), the reference product sponsor may assert in the 
22
action a total of not more than 20 patents of the type 
23
described in subparagraph (B), not more than 10 of which 
24
shall have issued after the date specified in section 
25
351(l)(7)(A) of such Act. 
26
00:09 Aug 13, 2019
H3991
3 
•HR 3991 IH
‘‘(B) The patents described in this subparagraph are 
1
patents that satisfy each of the following requirements: 
2
‘‘(i) Patents that claim the biological product 
3
that is the subject of an application under section 
4
351(k) of the Public Health Service Act (42 U.S.C. 
5
262(k)) (or a use of that product) or a method or 
6
product used in the manufacture of such biological 
7
product. 
8
‘‘(ii) Patents that are included on the list of 
9
patents described in section 351(l)(3)(A) of the Pub-
10
lic Health Service Act (42 U.S.C. 262(l)(3)(A)), in-
11
cluding as provided under section 351(l)(7) of such 
12
Act. 
13
‘‘(iii) Patents that— 
14
‘‘(I) have an actual filing date of more 
15
than 4 years after the date on which the ref-
16
erence product is approved; or 
17
‘‘(II) include a claim to a method in a 
18
manufacturing process that is not used by the 
19
reference product sponsor. 
20
‘‘(C) The court in which an action described in sub-
21
paragraph (A) is brought may increase the number of pat-
22
ents limited under that subparagraph— 
23
‘‘(i) if the request to increase that number is 
24
made without undue delay; and 
25
00:09 Aug 13, 2019
H3991
4 
•HR 3991 IH
‘‘(ii)(I) if the interest of justice so requires; or 
1
‘‘(II) for good cause shown, which— 
2
‘‘(aa) shall be established if the subsection 
3
(k) applicant fails to provide information re-
4
quired under paragraph (2)(A) that would en-
5
able the reference product sponsor to form a 
6
reasonable belief with respect to whether a 
7
claim of infringement under this section could 
8
reasonably be asserted; and 
9
‘‘(bb) may be established— 
10
‘‘(AA) if there is a material change to 
11
the biological product (or process with re-
12
spect to the biological product) of the sub-
13
section (k) applicant that is the subject of 
14
the application; 
15
‘‘(BB) if, with respect to a patent on 
16
the supplemental list described in section 
17
351(l)(7)(A) of Public Health Service Act 
18
(42 U.S.C. 262(l)(7)(A)), the patent would 
19
have issued before the date specified in 
20
such section 351(l)(7)(A) but for the fail-
21
ure of the Office to issue the patent or a 
22
delay in the issuance of the patent, as de-
23
scribed in paragraph (1) of section 154(b) 
24
00:09 Aug 13, 2019
H3991
5 
•HR 3991 IH
and subject to the limitations under para-
1
graph (2) of such section 154(b); or 
2
‘‘(CC) for another reason that shows 
3
good cause, as determined appropriate by 
4
the court. 
5
‘‘(D) In determining whether good cause has been 
6
shown for the purposes of subparagraph (C)(ii)(II), a 
7
court may consider whether the reference product sponsor 
8
has provided a reasonable description of the identity and 
9
relevance of any information beyond the subsection (k) ap-
10
plication that the court believes is necessary to enable the 
11
court to form a belief with respect to whether a claim of 
12
infringement under this section could reasonably be as-
13
serted. 
14
‘‘(E) The limitation imposed under subparagraph 
15
(A)— 
16
‘‘(i) shall apply only if the subsection (k) appli-
17
cant completes all actions required under paragraphs 
18
(2)(A), (3)(B)(ii), (5), (6)(C)(i), (7), and (8)(A) of 
19
section 351(l) of the Public Health Service Act (42 
20
U.S.C. 262(l)); and 
21
‘‘(ii) shall not apply with respect to any patent 
22
that claims, with respect to a biological product, a 
23
method for using that product in therapy, diagnosis, 
24
00:09 Aug 13, 2019
H3991
6 
•HR 3991 IH
or prophylaxis, such as an indication or method of 
1
treatment or other condition of use.’’. 
2
(b) APPLICABILITY.—The amendments made by sub-
3
section (a) shall apply with respect to an application sub-
4
mitted under section 351(k) of the Public Health Service 
5
Act (42 U.S.C. 262(k)) on or after the date of enactment 
6
of this Act. 
7
Æ 
00:09 Aug 13, 2019
H3991
